Paper Review Records
全部论文审稿周期
13 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
99
天
Scalable process technologies for human pluripotent stem cells (hPSCs) expansion and differentiation
作者
Kevin Cyrys; Robert Zweigerdt展开收起
作者单位
Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic Transplantation and Vascular Surgery (HTTG), Hannover Medical School (MHH), Carl Neuberg-Str. 1, Hannover 30625, Germany; REBIRTH Research Center for Translational and Regenerative Medicine, Hannover Medical School (MHH), Carl Neuberg-Str. 1, Hannover 30625, Germany展开收起
163
天
Toward bioengineered muscle–fat microphysiological systems for sports medicine and obesity therapeutics
作者
Min Young Kim; Anicca D. Harriot; Deok-Ho Kim展开收起
作者单位
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, United States; Center for Microphysiological Systems, Johns Hopkins University, Baltimore, MD 21205, United States; Division of Geriatrics and Gerontology, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD 21205, United States; Institute for NanoBio Technology, Johns Hopkins University, Baltimore, MD 21218, United States; Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, United States; Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, United States展开收起
134
天
Redox modulation of antitumor immunity via nanomedicine
作者
Xuanbo Zhang; Changrong Shi; Pei Huang; Xiaoyuan Chen展开收起
作者单位
School of Pharmaceutical Sciences, Hainan Medical University, Haikou, Hainan 571199, China; Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, 119074, Singapore; Center for Nuclear Medicine and Molecular Imaging, Shandong Cancer Hospital and Institute, Jinan 250117, China.展开收起
175
天
Cowpea mosaic virus as a candidate for intratumoral immunotherapy: progress, challenges, and future directions
作者
Ayumi E. Pottenger; Anthony O. Omole; Nicole F. Steinmetz展开收起
作者单位
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA, USA; Shu and K. C. Chien and Peter Farrell Collaboratory, University of California, San Diego, La Jolla, CA, USA; Center for Nano-ImmunoEngineering, University of California, San Diego, La Jolla, CA, USA; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA; Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA; Center for Engineering in Cancer, Institute of Engineering Medicine, University of California, San Diego, La Jolla, CA, USA; Department of Radiology, University of California, San Diego, La Jolla, CA, USA; Institute for Materials Discovery and Design, University of California, San Diego, La Jolla, CA, USA展开收起
112
天
High-Dose Subcutaneous Administration of Biologics: Overcoming Barriers Through Formulation and Device Innovation
作者
Tarik A. Khan; Deep Bhattacharya; Twinkle R. Christian; Melissa Holstein; Xiaoqing Hua; Roshan James; Bowen Jiang; Alexander Josowitz; Danielle Laiacona; Shrenik Mehta; Apurva More; Edel Mullen; Matthew Myers; Brendon Ricart; Timon Rickenbacher; Yongchao Su; Naveen Kumar Reddy Yaragudi展开收起
作者单位
Pharma Technical Development, Hoffmann-La Roche Ltd, Basel, Switzerland; BioTherapeutics Pharmaceutical Sciences, Pharmaceutical Research and Development, Pfizer, Andover, MA, United States; Process Development Attribute Sciences and Drug Product Technologies, Amgen, Thousand Oaks, CA, United States; Biologics Development, Bristol Myers Squibb, Devens, MA, United States; Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, United States; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States; Formulation and Process Development, Pre-Pivotal Biologics, Gilead Sciences Inc., Foster City, CA, United States; Pharmaceutical Development, Genentech, Inc., South San Francisco, CA, United States; Drug Product Development, Takeda, Lexington, MA, United States; Drug Product Technologies, Amgen, Cambridge, MA, United States; Analytical Development, Biologics CMC, Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, United States; Biologics CMC, Development Sciences, AbbVie, North Chicago, IL, United States; Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, NJ, United States; Global Process Development, Johnson & Johnson Innovative Medicine, Malvern, PA, United States展开收起
60
天
Microfluidics meets organoids: Kidney and bladder-on-Chip models for preclinical drug delivery assessment
作者
C. Ma; D. Koh; T. Nishimura; Y. Takata; Y. Kameda; R. Negoro; N. Ishiguro; M. Shibuta; I. Namatame; K. Tetsuka; T. Araoka; M. Takasato; J. Jang; J. Yoon; R. Yokokawa展开收起
作者单位
Department of Micro Engineering, Kyoto University, Kyoto 615-8540, Japan; Graduate School of Science and Technology, Division of Electronics and Mechanical Engineering, Gunma University, Gunma 376-8515, Japan; Physios Biotech, Inc., Iwate 020-0857, Japan; Research Institute, Nozaki Tokushukai Hospital, Daito, 574-0074, Japan; Department of Global Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; Astellas Pharma Inc., Tsukuba 305-8585, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; RIKEN Center for Biosystems Dynamics Research (BDR), Kobe 650-0047, Japan; Graduate School of Medicine, Osaka University, Suita 565-0871, Japan; Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan; Department of Mechanical Engineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea展开收起
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
